Novacyt (NCYT) Competitors GBX 38 +0.20 (+0.53%) As of 08/8/2025 11:57 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock NCYT vs. CREO, IUG, IHC, POLX, AVO, RUA, MHC, SUN, MXCT, and BELLShould you be buying Novacyt stock or one of its competitors? The main competitors of Novacyt include Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), Inspiration Healthcare Group (IHC), Polarean Imaging (POLX), Advanced Oncotherapy (AVO), RUA Life Sciences (RUA), MyHealthChecked (MHC), Surgical Innovations Group (SUN), MaxCyte (MXCT), and Belluscura (BELL). These companies are all part of the "medical devices" industry. Novacyt vs. Its Competitors Creo Medical Group Intelligent Ultrasound Group Inspiration Healthcare Group Polarean Imaging Advanced Oncotherapy RUA Life Sciences MyHealthChecked Surgical Innovations Group MaxCyte Belluscura Creo Medical Group (LON:CREO) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment. Which has more volatility & risk, CREO or NCYT? Creo Medical Group has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Novacyt has a beta of -1.86, meaning that its share price is 286% less volatile than the S&P 500. Is CREO or NCYT more profitable? Creo Medical Group has a net margin of -73.93% compared to Novacyt's net margin of -203.06%. Creo Medical Group's return on equity of -41.79% beat Novacyt's return on equity.Company Net Margins Return on Equity Return on Assets Creo Medical Group-73.93% -41.79% -20.09% Novacyt -203.06%-47.73%-27.98% Does the media favor CREO or NCYT? In the previous week, Creo Medical Group's average media sentiment score of 0.00 equaled Novacyt'saverage media sentiment score. Company Overall Sentiment Creo Medical Group Neutral Novacyt Neutral Do institutionals & insiders have more ownership in CREO or NCYT? 56.1% of Creo Medical Group shares are held by institutional investors. Comparatively, 0.1% of Novacyt shares are held by institutional investors. 22.4% of Creo Medical Group shares are held by insiders. Comparatively, 3.1% of Novacyt shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has higher valuation & earnings, CREO or NCYT? Creo Medical Group has higher revenue and earnings than Novacyt. Creo Medical Group is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCreo Medical Group£33.87M1.54-£25.04M-£6.32-2.05Novacyt£18.12M1.45-£36.80M-£54.44-0.70 SummaryCreo Medical Group beats Novacyt on 10 of the 11 factors compared between the two stocks. Get Novacyt News Delivered to You Automatically Sign up to receive the latest news and ratings for NCYT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NCYT vs. The Competition Export to ExcelMetricNovacytMedical Devices IndustryMedical SectorLON ExchangeMarket Cap£26.26M£3.53B£5.47B£3.07BDividend YieldN/A2.44%4.59%5.03%P/E Ratio-0.7079.7530.10170.60Price / Sales1.45101.43458.36303,757.13Price / Cash0.5815.9924.8427.96Price / Book0.383.968.524.52Net Income-£36.80M£132.05M£3.27B£5.90B7 Day Performance-2.80%0.58%4.65%1.08%1 Month Performance-5.61%3.09%0.96%3.52%1 Year Performance-18.28%18.68%36.43%61.48% Novacyt Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NCYTNovacytN/AGBX 38+0.5%N/A-18.3%£26.26M£18.12M-0.70120Positive NewsCREOCreo Medical GroupN/AGBX 13.15-0.8%N/A-54.6%£53.16M£33.87M-2.08279IUGIntelligent Ultrasound GroupN/AN/AN/AN/A£42.76M£6.57M-18.9165IHCInspiration Healthcare GroupN/AGBX 21-2.3%N/A-17.6%£18.19M£42.87M-1.44224Gap DownPOLXPolarean ImagingN/AGBX 1.05-2.3%N/A-44.8%£15.41M£5.21M-0.2728Gap UpAVOAdvanced OncotherapyN/AN/AN/AN/A£9.50MN/A-25.003,900Gap DownRUARUA Life SciencesN/AGBX 11.25-4.3%N/A+8.9%£6.98M£4.05M-2.6248Gap UpMHCMyHealthCheckedN/AGBX 12-4.0%N/A+15.8%£6.24M£9.43M-5.9916Gap DownSUNSurgical Innovations GroupN/AGBX 0.66-6.3%N/A-6.0%£6.12M£12.54M-21.1180Gap DownMXCTMaxCyteN/AGBX 2.25-0.9%N/A-99.6%£2.97M£57.52M-0.0880High Trading VolumeBELLBelluscuraN/AGBX 0.75flatN/AN/A£1.89M£2.87M-0.0824 Related Companies and Tools Related Companies Creo Medical Group Alternatives Intelligent Ultrasound Group Alternatives Inspiration Healthcare Group Alternatives Polarean Imaging Alternatives Advanced Oncotherapy Alternatives RUA Life Sciences Alternatives MyHealthChecked Alternatives Surgical Innovations Group Alternatives MaxCyte Alternatives Belluscura Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:NCYT) was last updated on 8/11/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novacyt S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novacyt With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access Sale